Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Avutometinib,Defactinib
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Drug Combination Shows Promise in Treatment-Resistant Advanced Ovarian Cancer
Details : The treatment combination comprised VS-6766 and defactinib, which can potentially hinder signals ovarian cancer to grow. VS-6766 is a dual RAF/MEK inhibitor of Verastem Oncology while defactinib is a FAK inhibitor.
Product Name : VS-6766
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 19, 2021
Lead Product(s) : Avutometinib,Defactinib
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Daratumumab
Therapeutic Area : Oncology
Study Phase : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
New Type of Treatment Could Reawaken Immune Response Against Prostate Cancer
Details : Study suggests that therapies which target CD38-such as the multiple myeloma drug daratumumab-could hold promise against prostate cancer too, by reawakening the anti-cancer immune response.
Product Name : Darzalex
Product Type : Antibody
Upfront Cash : Inapplicable
July 05, 2021
Lead Product(s) : Daratumumab
Therapeutic Area : Oncology
Highest Development Status : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Olaparib
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Trial shows Benefits of Targeted Drug Against Early-Stage Breast Cancer with Inherited BRCA Mutation
Details : The OlympiA trial showed that adding olaparib for one year following standard treatment for patients who had an inherited BRCA mutation and early-stage, HER-2 negative breast cancer, cut the risk of their breast cancer returning by 42 per cent at a media...
Product Name : Lynparza
Product Type : Cytotoxic Drug
Upfront Cash : Inapplicable
April 06, 2021
Lead Product(s) : Olaparib
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : EP0042
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Ellipses Pharma
Deal Size : Inapplicable
Deal Type : Inapplicable
Resistance-Busting ICR Drug Enters Clinical Trial
Details : Ellipses Pharma has rapidly progressed the development of EP0042 following successful negotiations between the ICR and the company, which were led by our Business and Innovation Office.
Product Name : EP0042
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 19, 2021
Lead Product(s) : EP0042
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Ellipses Pharma
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : BAY1895344
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Bayer AG
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The ataxia telangiectasia and Rad3-related (ATR) inhibitor BAY 1895344 showed promise in patients with a range of advanced, heavily pre-treated cancers, including breast, bowel, and prostate tumors in a dose-escalation portion of a first-in-human phase 1...
Product Name : BAY 1895344
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 28, 2020
Lead Product(s) : BAY1895344
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Bayer AG
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Olaparib,Capivasertib
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : First trial to use the pioneering genetically targeted drug olaparib - already licensed for ovarian, breast and prostate cancer - together with a promising new medicine, called capivasertib.
Product Name : Lynparza
Product Type : Cytotoxic Drug
Upfront Cash : Inapplicable
September 14, 2020
Lead Product(s) : Olaparib,Capivasertib
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : PLX4720,Talimogene Laherparepvec
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Oracle Cancer Trust
Deal Size : Inapplicable
Deal Type : Inapplicable
Researchers Target Thyroid Cancer with Triple Threat Drug Combination
Details : The BRAF drug, called PLX4720, which targets this genetic mutation, was developed at the ICR, and produces significant results in both thyroid cancers and melanomas which carry the mutation.
Product Name : PLX4720
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 12, 2020
Lead Product(s) : PLX4720,Talimogene Laherparepvec
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Oracle Cancer Trust
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Capivasertib,Fulvestrant
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : AstraZeneca
Deal Size : Inapplicable
Deal Type : Inapplicable
Breast Cancer Drug Capivasertib Enters Major Trial
Details : The CAPItello-291 trial will examine the effects of the drug in pre-menopausal or post-menopausal women, and men, with an advanced form of oestrogen receptor (ER) positive, human epidermal growth factor receptor 2 (HER2) negative breast cancer.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 26, 2020
Lead Product(s) : Capivasertib,Fulvestrant
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : AstraZeneca
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Fadraciclib
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Cyclacel Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Scientists at The Institute of Cancer Research, London, have found an indirect way to target N-Myc, in a move that could be a game-changer for children with aggressive neuroblastoma.
Product Name : CYC065
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 10, 2020
Lead Product(s) : Fadraciclib
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Cyclacel Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable